Strong Financial Performance
BWXT reported 12% organic revenue growth, 20% adjusted EBITDA growth, and a 29% increase in total revenue for Q3 2025.
Record Backlog
The company achieved a total backlog of $7.4 billion, up 23% from the last quarter and 119% year-over-year.
Commercial Operations Surge
Commercial Operations reported a 122% revenue increase, with organic growth of 38%, driven by Kinectrics acquisition and growth in commercial nuclear power and medical isotopes.
New Major Contracts
BWXT was awarded a $1.5 billion defense fuels contract and a $1.6 billion contract for high-purity depleted uranium, signaling strong growth in special materials.
Positive Commercial Nuclear Market Outlook
Commercial Power revenue grew significantly, with strong demand for small modular reactors (SMRs) and large reactors, and new contracts with Rolls-Royce for SMR steam generators.